Tacrolimus

Indications

Tacrolimus is available in various formulations and is utilized for distinct therapeutic purposes. The immediate-release formulations are prescribed for the prophylaxis of organ rejection in both adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in conjunction with other immunosuppressive agents. The extended-release formulations of tacrolimus are specifically indicated for preventing organ rejection in adult and pediatric patients undergoing kidney transplants, and may also be employed in patients transitioning from immediate-release forms. Topical tacrolimus ointment serves as a second-line therapy for the short-term and intermittent management of moderate-to-severe atopic dermatitis in non-immunocompromised individuals, comprising both adults and children, particularly when other topical treatments prove inadequate or alternative treatments are not advisable. The higher and lower strength ointments are indicated for adults, whilst only the lower strength formulation (0.03%) is approved for pediatric patients aged between 2 and 15 years.

Pharmacodynamics

The mechanism of action of tacrolimus involves the inhibition of peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12, thereby forming a new complex that disrupts T-lymphocyte signal transduction and halts IL-2 transcription. Although tacrolimus exhibits pharmacological similarities to cyclosporine, it is associated with lower rejection rates. Beyond its immunosuppressive capabilities, tacrolimus is also effective in the topical treatment of atopic dermatitis, offering an anti-inflammatory effect akin to steroids but with a comparatively milder potency. Notably, tacrolimus offers dermatological advantages as it can be safely applied to facial areas, unlike topical steroids which can result in significant skin thinning.

Absorption

The absorption of tacrolimus after oral administration displays considerable variability and is incomplete. In adult kidney transplant patients, the absolute bioavailability is recorded at 17±10%, while for adult liver transplant patients, it is 22±6%. For healthy volunteers, the bioavailability is approximately 18±5%, and in pediatric liver transplant patients, it stands at 31±24%. Tacrolimus's maximum blood concentrations (Cmax) and the area under the curve (AUC) increase proportionately with dosage. In a study involving fasted healthy volunteers, the greatest rate and extent of absorption were observed when tacrolimus was administered without food, highlighting the significance of timing relative to meals. When consumed immediately after a meal, mean Cmax decreased by 71% and mean AUC by 39%. Administered 1.5 hours post-meal, similar reductions in Cmax (63%) and AUC (39%) were observed compared to the fasted state.

Metabolism

Tacrolimus undergoes extensive metabolism primarily via the cytochrome P450 enzyme CYP3A4, with secondary involvement of CYP3A5. It is metabolized into eight different metabolites, including 13-demethyl tacrolimus, 31-demethyl tacrolimus, and 15-demethyl tacrolimus among others. The predominant metabolite, as identified in studies involving human liver microsomes, is 13-demethyl tacrolimus. Moreover, in vitro research indicates that the 31-demethyl metabolite retains the same bioactivity as the parent compound, tacrolimus.

Mechanism of Action

Tacrolimus exhibits its pharmacological effects primarily through the inhibition of T-lymphocyte activation. It achieves this by binding to the intracellular protein FKBP-12, forming a complex with calcium, calmodulin, and calcineurin. This complex subsequently inhibits the phosphatase activity of calcineurin. As a result, the dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NF-AT) is prevented, which is believed to be a key step in initiating the transcription of genes responsible for lymphokine production. Furthermore, tacrolimus suppresses the transcription of several cytokine genes, including IL-3, IL-4, IL-5, GM-CSF, and TNF, which play significant roles in the early activation of T-cells. In addition to these effects, tacrolimus inhibits the release of pre-formed mediators from mast cells and basophils in the skin, as well as downregulates the expression of FceRI on Langerhans cells. While these mechanisms have been observed, their precise clinical relevance in the context of atopic dermatitis remains to be fully elucidated.